Abstract

Background: High cerebrospinal fluid (CSF) and plasma levels of homocysteine (HC) have been reported in certain neurodegenerative disorders, such as Alzheimer’s, Parkinson’s diseases and, recently, amyotrophic lateral sclerosis (ALS). Objectives: To assay the CSF and plasma levels of HC in ALS patients and controls, and to evaluate the relationship between HC levels and clinical variables of the disease. Methods: Cerebrospinal fluid from sixty-nine (M/F 1.87) and plasma from sixty-five ALS patients (M/F 1.83) were taken and stored at −80°C until use. Controls (CSF = 55; plasma = 67) were patients admitted to our hospital for neurological disorders with no known relationship to HC changes. CSF and plasma from ALS patients and controls were obtained as a necessary step of the diagnostic workup. HC levels in CSF and plasma were assayed using a high performance liquid chromatograph (HPLC) and a fluorimeter detector. Results: The median level of total HC in the CSF of ALS patients was 0.46 μM, significantly higher than that of the controls (0.24 μM, +91.6%, P < 0.001). A similar trend was observed when HC was assayed in plasma (ALS, 12.4 μM vs. controls, 7.26 μM, +70.8%, P < 0.001). The CSF and plasma HC levels showed no relationship with the disease progression, age at onset, and the site of onset. Conclusions: Homocysteine is a biochemical marker in ALS, and it might be related to the pathophysiology of the disease.
Lingua originaleEnglish
pagine (da-a)84-89
Numero di pagine6
RivistaEuropean Journal of Neurology
Volume17
Stato di pubblicazionePublished - 2010

Fingerprint

Amyotrophic Lateral Sclerosis
Homocysteine
Cerebrospinal Fluid
Nervous System Diseases
Age of Onset
Neurodegenerative Diseases
Parkinson Disease
Disease Progression
Biomarkers

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neurology

Cita questo

@article{531bd66cc63f4a0f894b29c0a0869455,
title = "Elevated cerebrospinal fluid and plasma homocysteine levels in ALS",
abstract = "Background: High cerebrospinal fluid (CSF) and plasma levels of homocysteine (HC) have been reported in certain neurodegenerative disorders, such as Alzheimer’s, Parkinson’s diseases and, recently, amyotrophic lateral sclerosis (ALS). Objectives: To assay the CSF and plasma levels of HC in ALS patients and controls, and to evaluate the relationship between HC levels and clinical variables of the disease. Methods: Cerebrospinal fluid from sixty-nine (M/F 1.87) and plasma from sixty-five ALS patients (M/F 1.83) were taken and stored at −80°C until use. Controls (CSF = 55; plasma = 67) were patients admitted to our hospital for neurological disorders with no known relationship to HC changes. CSF and plasma from ALS patients and controls were obtained as a necessary step of the diagnostic workup. HC levels in CSF and plasma were assayed using a high performance liquid chromatograph (HPLC) and a fluorimeter detector. Results: The median level of total HC in the CSF of ALS patients was 0.46 μM, significantly higher than that of the controls (0.24 μM, +91.6{\%}, P < 0.001). A similar trend was observed when HC was assayed in plasma (ALS, 12.4 μM vs. controls, 7.26 μM, +70.8{\%}, P < 0.001). The CSF and plasma HC levels showed no relationship with the disease progression, age at onset, and the site of onset. Conclusions: Homocysteine is a biochemical marker in ALS, and it might be related to the pathophysiology of the disease.",
author = "Marcello Ciaccio and {La Bella}, Vincenzo and Daniela Butera and Giulia Bivona and Tommaso Piccoli and Francesca Valentino and Piera Paladino and Marco Fazzari",
year = "2010",
language = "English",
volume = "17",
pages = "84--89",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Elevated cerebrospinal fluid and plasma homocysteine levels in ALS

AU - Ciaccio, Marcello

AU - La Bella, Vincenzo

AU - Butera, Daniela

AU - Bivona, Giulia

AU - Piccoli, Tommaso

AU - Valentino, Francesca

AU - Paladino, Piera

AU - Fazzari, Marco

PY - 2010

Y1 - 2010

N2 - Background: High cerebrospinal fluid (CSF) and plasma levels of homocysteine (HC) have been reported in certain neurodegenerative disorders, such as Alzheimer’s, Parkinson’s diseases and, recently, amyotrophic lateral sclerosis (ALS). Objectives: To assay the CSF and plasma levels of HC in ALS patients and controls, and to evaluate the relationship between HC levels and clinical variables of the disease. Methods: Cerebrospinal fluid from sixty-nine (M/F 1.87) and plasma from sixty-five ALS patients (M/F 1.83) were taken and stored at −80°C until use. Controls (CSF = 55; plasma = 67) were patients admitted to our hospital for neurological disorders with no known relationship to HC changes. CSF and plasma from ALS patients and controls were obtained as a necessary step of the diagnostic workup. HC levels in CSF and plasma were assayed using a high performance liquid chromatograph (HPLC) and a fluorimeter detector. Results: The median level of total HC in the CSF of ALS patients was 0.46 μM, significantly higher than that of the controls (0.24 μM, +91.6%, P < 0.001). A similar trend was observed when HC was assayed in plasma (ALS, 12.4 μM vs. controls, 7.26 μM, +70.8%, P < 0.001). The CSF and plasma HC levels showed no relationship with the disease progression, age at onset, and the site of onset. Conclusions: Homocysteine is a biochemical marker in ALS, and it might be related to the pathophysiology of the disease.

AB - Background: High cerebrospinal fluid (CSF) and plasma levels of homocysteine (HC) have been reported in certain neurodegenerative disorders, such as Alzheimer’s, Parkinson’s diseases and, recently, amyotrophic lateral sclerosis (ALS). Objectives: To assay the CSF and plasma levels of HC in ALS patients and controls, and to evaluate the relationship between HC levels and clinical variables of the disease. Methods: Cerebrospinal fluid from sixty-nine (M/F 1.87) and plasma from sixty-five ALS patients (M/F 1.83) were taken and stored at −80°C until use. Controls (CSF = 55; plasma = 67) were patients admitted to our hospital for neurological disorders with no known relationship to HC changes. CSF and plasma from ALS patients and controls were obtained as a necessary step of the diagnostic workup. HC levels in CSF and plasma were assayed using a high performance liquid chromatograph (HPLC) and a fluorimeter detector. Results: The median level of total HC in the CSF of ALS patients was 0.46 μM, significantly higher than that of the controls (0.24 μM, +91.6%, P < 0.001). A similar trend was observed when HC was assayed in plasma (ALS, 12.4 μM vs. controls, 7.26 μM, +70.8%, P < 0.001). The CSF and plasma HC levels showed no relationship with the disease progression, age at onset, and the site of onset. Conclusions: Homocysteine is a biochemical marker in ALS, and it might be related to the pathophysiology of the disease.

UR - http://hdl.handle.net/10447/71830

M3 - Article

VL - 17

SP - 84

EP - 89

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

ER -